Caption Management’s Silence Therapeutics SLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.23M Buy
+112,300
New +$1.37M 0.01% 1180

Other funds holding SLN

Caption Management's SLN Position: Q3 2026 in Review

Caption Management increased its Silence Therapeutics (SLN) stake by 219% in Q3 2026, buying an estimated $4.33M and bringing the position to 518,674 shares worth $5.67M. The position accounts for 0.02% of the portfolio, ranked #615.

Caption Management first reported a position in SLN in Q2 2026 and has held it in 2 quarters since. 92 funds tracked by Wall St. Rank hold SLN as of Q3 2026.

  • Caption Management held 518,674 shares of Silence Therapeutics worth $5.67M as of Q3 2026.
  • Caption Management bought 356,198 Silence Therapeutics shares in Q3 2026, an estimated $4.33M.
  • Silence Therapeutics made up 0.02% of Caption Management's portfolio in Q3 2026, its #615 holding.
  • Caption Management first reported a position in Silence Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 92 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2026.

Based on Caption Management's 13F filing for Q3 2026, filed 16 Nov 2026.